Novo Nordisk Diabetes Drugs

Ozempic, Novo Nordisk and chronic kidney disease

FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

The Wall Street Journal on MSN · 2d

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

Reuters on MSN · 2d

US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression

Novo's blockbuster diabetes drug Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as its popular obesity treatment Wegovy. The U.S. Food and Drug Administration's approval makes the drug,

Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

6don MSN

Novo Nordisk Shares Surge on New Obesity Drug Results

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients ...

NBC Bay Area3d

FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The ...

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results